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INTRODUCTION 
 
 FNAC remains the first choice for the initial investigation and 
diagnosis of both superficial and deep lesions though core needle biopsy 
is extremely valuable in selected cases. 
 
 Clinical value of FNAC is not only limited to neoplastic 
conditions, but also valuable in the diagnosis of inflammatory, 
infectious and degenerative conditions. 
 
 It is relatively painless, produces a speedy result and cheap. Its 
accuracy in many situations can approach that of histopathology in 
providing  an unequivocal diagnosis in the experienced hands. It is 
applicable to lesions that are easily palpable. 
 
 The risk of needle tract seedling is extremely low when truly fine 
needles of 22 gauge or less are used. 
 
 The success of FNAC depends on representativeness and 
adequacy of sample and high quality of preparation. 
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 At the community level, FNAC may be regarded as simple 
screening test for serious disease, which needs further investigation and 
referral to specialist. 
 
 In the major hospital, it is an essential component of the final 
preoperative or pretreatment investigations on which the management of 
the problem is based. 
 
 “There would be so little danger in extracting a small quantity of 
tissue from an obscure growth by the aid of a needle, trocar or cannula, 
so little substance is there necessary for the microscope that the 
diagnosis of cancer would no longer be embracing or vogue.” 
VELPEAU 1856 
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HISTORICAL DEVELOPEMENT 
 
 At about the sametime histopathologist and cytologist began their 
tentative initiatives, Leyden and 3years later, Menetrier employed 
needles to obtain cells and tissue fragments. 
 
 In the UK in 1927, Dudgeon and Patrick proposed the needling of 
tumors as a means of rapid microscopic diagnosis. 
 
 Similarly Martin and Ellis at memorial hospital in USA were also 
advocates of needle aspiration. 
 
 In Europe particularly Scandinavia FNAC as the technique began 
to flourish in 1950s and 1960s. 
  
 Abulkasim, an Arabian physician, in 10th century was credited for 
using the technique. Dating back to 1904, when Greig and Gray 
aspirated a lymphonode to diagnose Trypanosomiasis, the clinical use of 
aspiration cytology was introduced for the first time in the history. Fine  
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needle aspiration cytology has been used in Sweden since 1950. It does 
not supplement histology but augments it. 
 
 The earlier microscopist like Malphiggi and Virchow looked at 
scrappings and fluids under microscope and described their findings. 
 
 In 1858, Rudolf Virchow, published his cellular physiology, Ward 
in 1912, used FNAC to examine lymphnode for lymphoma. 
 
 Guthrie in 1921 first used lymphnode aspiration on a systematic 
basis. 
 
 In 1957 Gibson and Smith published their report on FNAC. At the 
Radium hemmet in Stockholm about 12000 aspirations were performed 
every year, 2000 on thyroid alone. Other centers using this technique on 
a large scale are the “Harzen Institute of Oncology” in Moscow and the 
Curie foundation at Paris. 
 
 A current authoritative view on FNAC of thyroid Neoplasm has 
been published by Lowhagen et al 1979 and Chu et al 1979. 
5 
 There is a large body of world literature attesting to its accuracy 
and advantages, although the need for caution in interpretation, 
meticulous attention to the technique and the limitations of diagnosis are 
also well documented. 
 
 Of the many workers it was Johannes Muller who set the 
foundation of clinical cytology. In 1938 he published on the nature and 
structural characteristic of cancer and those morbid growth that may be 
confended with it. 
  
 In most hospital in UK the aspirations are performed by the 
clinicians, who send slides directly to the laboratory. As the equipment 
needed for FNAC is minimal, it can be performed in the clinic, ward or 
even in the patients home. In most cases, definite answer can be given 
and if a cytological diagnosis of malignant cell is made, histological 
confirmation prior to definite treatment is not required. On the other 
hand, a report of “No malignant cells seen” doesnot excludes cancer. If 
there is any doubt in the mind of the cytologist it is indicated so in the 
report and a formal biopsy of frozen section is performed. A positive 
result is significant. Whereas a negative result may not be so. 
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Seedling of tumour cells along fine needle tract is virtually 
unknown. Presently FNAC is routinely done in many centers also in 
India. With further advance, the accuracy rate has been increased with 
the analysis of DNA content of the aspirates and correlation of cytology 
examination with DNA analysis offers unique opportunity to obtain an 
accurate diagnosis in thyroid neoplasms (Atkin N.B: Br.J.Cancer 40:210 
– 221, 1979) 
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AIM OF THIS DISSERTATION 
 
 The aim of this dissertation is to evaluate the accuracy of fine 
needle aspiration cytology to diagnose common surgical conditions in 
consecutive 200 cases. 
 
 Correlation of FNAC results with postoperative Histopathological 
reports. 
 
 Analysis of sensitivity and false positive results of FNAC in 
common surgical conditions like 
 
1. Salivary gland tumours. 
2. Lymphnode swellings. 
3. Thyroid gland swellings. 
4. Breast lumps. 
5. Soft tissue swellings. 
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MATERIALS, METHODS AND TECHNIQUE 
 
MATERIALS 
 
1. Disposable (Gamma-irradiated)hypodermic needles of size 
23 and of length between 1 to 11/2 inches. 
 
2. Disposable sterile 5 ml syringe. Pistol syringe holder 
(Cameco Syringes) is preferred. But here it’s not used. 
 
3. Swabs with spirit (or) skin sterlising solutions. 
 
4. Several 76 x 26 mm size microscope slides are suitably 
labeled and numbered with suitable instrument.  
 
5. Koplin – Jar for keeping the smeared slides in the fixative, 
the fixative being Isopropyl alcohol. 
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6. Small transport box for slide preparations in which the 
specimen slides are held separately so that the face of the 
slide is not damaged and not contaminated during 
transportation. 
 
7. Complete laboratory request form with full clinical details. 
 
8. Stain: Hematoxylin and Eosin stains 
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SAMPLE TECHNIQUE 
 
 The skin is cleaned and the lump is located and firmly held 
between the thumb and the fore finger of the free hand. The syringe is 
held by outside of the barrel and the needle tip is pushed into the lesion 
vertically. The plunger is partially retracted, creating a negative 
pressure, without loosing the pressure or pulling the needle tip out of 
skin, the whole syringe is rotated by the movement of the wrist and 
gently moved in and out. The cutting edge of the needle tip frees the 
cells inside the lesion, which are sucked into the fine bore of the needle. 
 
 Using continuous negative pressure by pulling firmly on the 
plunger of the syringe, guide the cutting tip of the needle forwards and 
backwards and obliquely through the firmly held lump and twisting the 
wrist to apply a rotating as well as a forward and backward action, the 
cells are sucked into the lumen of the needle. 
 
 Nothing is usually visible in the body of the syringe between the 
bottom of the plunger and the needle head, a cyst being an obvious 
exception. 
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 Now, slowly release the pressure on the plunger so that there is no 
more suction effect. Withdraw the syringe and the needle gently from 
the skin. It is important, releasing of the pressure is not performed 
before removing the needle, air will rush up the needle and loose the 
specimen into the body of the syringe. 
 
EXPELLING THE BIOPSY MATERIAL: 
 
 After the needle is withdrawn from the patient, it is removed from 
the syringe.The syringe filled with air and the needle is replaced firmly. 
Some workers using an air reservoir technique is not used here. 
 
 The syringe is held vertically with the needle tip above the surface 
of the microscopic slide, the plunger is pushed down and the contents of 
the needle are blown gently on the slide or slides. 
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MAKING OF A SMEAR: 
 
 
DIRECT SMEAR 
 
 
 When the cells are adequate we can directly make the smear. 
 
INDIRECT SMEAR: 
 
 
 When the cells are inadequate we have to centrifuge the aspirates 
and then can make the smear. 
 
 
HEMATOXYLIN AND EOSIN STAINING FOR FNAC OF 
SWELLINGS. 
 
1. Cellular preparation are made rapidly as described above 
and with as little trauma to the cells as possible. For 
fixation, the slides are immersed in 100% Isopropyl alcohol 
for a minimum of 30 minutes. 
2. Then the slides are stained with Haematoxylin for 
10minutes. 
3. Then, the slides are washed in tap water and differentiated 
in acid alcohol. 
4. Then, the slides are left in running water for blueing  
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5. The slides are stained with Eosin for 2minutes. 
6. Then the slides are washed and dried and mounted. 
 
Two slides are prepared for each case. 
 
 When aspirating the thyroid, a vascular organ, a bloody aspirate is 
sometimes obtained. A technique similar to that of karolinska Institute, 
Stockholm is used, the syringe contents are emptied quickly on to one or 
two slides before the blood clots. If there is semisolid material on the 
slide, the spreader slide is turned over and the flat surface is pressed 
gently on to those tiny fragments and the slides pulled apart ending up 
with evenly spaced cells on both slide surfaces. 
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REVIEW OF LITERATURE 
 
Fine needle aspiration cytology is not the substitute for 
histopathological examination. It is used in conjunction with clinical and 
radiological findings to provide best possible initial assessment on 
which management decisions can be based. 
 
Team work, careful technique and enthsiasm for FNAC are essential 
factors while actual organization of the work can be modified to suit 
local conditions. 
 
SALIVARY GLANDS: 
 
 Salivary glands are not subjected to incisional or core neelde 
biopsy because of risk of fistula and in neoplasm for fear of tumour 
implant  
 
 More than 50% of the swellings are  Non-neoplastic. 
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ACCURACY:  
 
From the karolinska study, FNAC accuracy for salivary gland 
neoplasms are more than 90%. 
 
More than 90% pleomorphic adenoma and most malignant 
tumours are diagnosed correctly. 
 
In a review in 1994, sensitivity was 81-100%, specificity was 94-
100% and accuracy of typing was between 61 and 80% 
 
Heterogenous structure of many salivary gland tumours inevitably 
limits the accuracy of FNB due to small size and selective character of 
the sample. 
 
Diagnosis of pleomorphic adenoma and warthins tumour are easy. 
 
False negativity are related to cystic tumours, warthins tumour, 
mucoepidermiod carcinoma, acinic cell carcinoma etc. 
 
False positive results are related to regenerative epithelial 
hyperplasia and squamous metaplasia in sialadenitis or warthins. 
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Hyaline globules in monomorphic adenoma are misdiagnosed as 
Adenoid cystic carcinoma. 
Distinction between primary and metastatic carcinoma is difficult 
in poorly differentiated carcinoma. 
 
LYMPHNODE: 
 
 Commonest cause of peripheral lymphadenopathy is reactive. 
 
 Cytological examination can decide whether the 
lymphadenopathy is due to reactive hyperplasia, metastatic or malignant 
lymphoma. 
 
 Commercially produced monoclonal antibodies to various 
antigens assists the pathologist in identification of the source of tumour 
metastasis.  
 
 The role in diagnosis of lymphoma is to confirm a clinical 
suspicion or to exclude with confidence. Cytological diagnosis of NHL 
is confirmed by open biopsy and histopathological examination for 
defining diagnosis and subtyping. 
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 Preop FNB does not adversely affect subsequest histological 
examination of the node. 
 
ACCURACY: 
 
 The diagnosis of metastatic malignancy is influenced by size and 
site of lymph node, fibrosis, previous radiation and number of punctures 
made. 
 
 Diagnostic specificity is high. 
 
 The diagnostic accuracy not only depends on representativeness 
of the aspirate but also on the quality of cytological preparation.  
 
 Dignostic sensitivity is significantly lower for lymphoma than 
metastatic malignancy. 
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THYROID GLAND: 
 
FNAC is the fistline diagnostic test for evaluation of goiter and 
single most effective test for preoperative diagnosis of solitary nodule 
thyroid. 
 
The main indications for FNAC are : 
 
1. Diagnosis of diffuse non-toxic goiter  
2. diagnosis of SNT or dominant thyroid nodule  
3. confirmation of clinically obvious thyroid malignancy. 
4. To obtain material for special laboratory investigations aimed at 
definite prognostic parameters. 
 
Prevalence of palpable thyroid nodule is about 4% and less than 
5% of these nodules are malignant. 
 
 FNAC confirms benignity in about 60%. In diffuse non-toxic 
goiter FNAC distincts between colloid goiter and autoimmune 
thyroiditis. 
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FNAC provides a more rapid safe and accurate diagnosis of the 
SNT. The proportion of malignancy in surgically resected nodules may 
increase to 40% compared with 8-20% before the use of FNAC. 
 
Confirmation of obvious malignancy, in particular, anaplastic 
carcinoma and malignant lymphoma, spares the patient additional 
invasive diagnostic procedures. 
 
ACCURACY: 
 
 FNAC is highly accurate in the diagnosis of thyroiditis. 
 
 In view of asheroft and vanhale, FNAC is shown to achieve a 
diagnostic accuracy of over 90% in terms of predictive value, 
sensitivity, specificity and efficiency in diagnosis of neoplasms. 
 
 False negativity in relation to cystic neoplasm, cystic papillary 
carcinoma is more than 40% . 
 
 False negative diagnoses also arise from inadequate samples, 
geographic misses of the lesion, dual pathology and errors in 
interpretation.     
20 
Repeat FNB Samplings over a period of time reduces the false 
negative rates. 
 
 False Positivity is low, is around 1-3% in malignancy. It is 
minimal in anaplastic carcinoma or high grade lymphoma. 
 
 False negativity is high in very well differentiated follicular 
carcinoma and Low or intermediate grade lymphoma. 
 
BREAST: 
 
 A preoperative diagnosis offers several advantages in a palpable 
breast lump 
 
1. Immediate diagnosis relieves the patient’s anxiety. 
2. Definite treatment is planned in advance 
3. If cancer is confirmed, Staging investigations can be arranged. 
4. Some benign conditions confidently diagnosed and surgery 
avoided. 
5. Need for frozen section diagnosis is reduced. 
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FNB and mammography as compliments to clinical examination 
(triple assessment) have become the standard approach to the 
investigation of palpable breast lumps. 
 
USG is useful in young women 
 
Aspirated cell material can be used for hormone receptor analysis 
and various quantitative investigations such as morphometry, DNA 
measurement and cell kinetics. 
 
FNB of a palpable breast lumps should be preceded by 
mammographic examination as radiological findings may influence the 
choice of the area to be biopsied. 
 
ACCURACY: 
 
Sensitivity of FNAC in diagnosis of breast carcinoma is 90-95%.  
The aim is not to be less than 95%  
 
Sensitivity is reduced for invasive lobular carcinoma, smaller and 
very large cancers and DCIS. 
 
Positive predictive value of a malignancy diagnosis is high. 
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Best results are achieved if the pathologist who reads the smears, 
also performs the biopsies. 
 
Insitu carcinoma constitutes special problem since it is impossible to 
decide if invasion is present or not.  High grade and large cell DCIS is 
easily recognized as malignant in FNB. 
 
Low grade and small cell intraduct carcinomas of papillary or 
cribriform type may not show an obviously malignant cytological 
pattern, reported as suspicious or atypical with recommendations for 
open biopsy. 
 
False negative results is usually less than 5%  
 
Diagnostic accuracy is over  99% in triple assessment. 
 
SUBCUTIS AND SOFT TISSUE: 
 
The use of FNB and cytodiagnosis in the primary evaluation of a 
mass in the skin, subcutis or soft tissues is still debated. 
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Pretreatment diagnosis relieves patient’s anxiety by providing instant 
diagnosis, followed by discussion of Therapeutic options. 
 
Subcutaneous lipoma is one of the commonest tumours, on rare 
occasions have had surprise findings.  FNB confirmation is justified in 
such circumstances. 
 
Present use of FNB as primary and often definite diagnosis of soft 
tissue tumours before treatment is based on the following. 
 
1. Treatment of majority of soft tissue tumours is surgery.  
Specific histiogenic type is less important than site, size and 
relation to Vessels, Nerves and Bone. 
 
2. Essential to accurately identify as benign or malignant and to 
exclude other malignancies or reactive process. 
 
3. Planning of management is based on the combined evaluation 
of clinical data, radiological findings and cytological 
examination. 
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ACCURACY 
 
 Result of FNAC of soft tissue tumours are promising if patients 
suspected of malignancy are referred to centers specialising in this field. 
 
 Akerman et al reported in his series insufficient material is 6% of 
Specimens, erroneous cytological diagnosis in 5%. 
 
 85% benign tumours were reported as benign. 
 
 89% of sarcomas reported as malignant soft tissue tumours. 
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DISORDERS OF SALIVARY GLANDS 
 
 There are four main salivary glands and multiple minor salivary 
glands. 
 
PAROTID TUMOURS: 
 
• Most common is pleomorphic Adenoma (80-90%) 
• Low grade malignant tumours cannot be distinguished from 
benign neoplasms  
• High grade tumours grow rapidly are usually painful and often 
have lymphnode involvement at presentation. 
• CT and MRI are useful 
• FNAC is better than open biopsy 
• Tumours should be excised, not enucleated 
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CLASSIFICATION 
 
TYPE SUBGROUP EXAMPLES 
I. Adenoma Pleomorphic 
Monomorphic 
PleomorphicAdenoma  
Warthin’s tumour 
II.Carcinoma Low grade Acinic cell carcinoma  
Adenoid cystic carcinoma  
low grade mucoepidermoid      
                carcinoma. 
 High grade Adenocarcinoma  
Squamous cell carcinoma  
High grade mucoepidermoid      
                 carcinoma 
III. Non-epithelial   
               tumours 
 Hemangioma 
 Lymphagioma 
IV. Lymphomas Primary  Non-Hodgkin’s 
 Secondary Lymphoma in Sjogren 
Syndrome 
V.Secondary tumours Local  
Distant 
Head and Neck tumours  
skin and bronchus 
VI. Unclassified   
VII. Tumour like  
               lesions 
Solid Adenomatoid hyperplasia, 
 Benign Lymphoepithelial lesion
 Cystic Salivary gland cysts 
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TNM STAGING 
 
 
Tumour: 
 
 
 
 
TX  - Primary tumour can not be assessed. 
T0 - No evidence of Primary tumour. 
Tis - Carcinoma insitu. 
T1 - Tumours  2cm or less without extraparenchymal extension. 
T2 - Tumours 2cm – 4cm without extraparenchymal extension. 
T3 - Tumours having extraparenchymal extension without VIIth 
  nerve involvement and/or 4cm-6cm in greatest dimension. 
T4 - Tumours invade base of skull, VIIth nerve and /or >6cm. 
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Node: 
 
Nx - Regional nodes can not be assessed. 
N0 - No regional node metastasis. 
N1 - Single ipsilateral node 3cm or less size. 
N2 - N2a - Single ipsilateral node 3-6cm size 
N2b - Multiple ipsilateral nodes, no more than 6cm  
  size. 
N2c - Bilateral or contralateral lymphnodes, no more  
        than 6cm size. 
N3 - Metastasis in lymphnode > 6cm size 
 
Metastasis: 
 
Mx - Metastasis can not be assessed 
M0 - No distant metastasis 
M1 - Distant Metastasis. 
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THYROID 
 
CLASSIFICATION OF THYROID SWELLINGS: 
Simple Goitre (Euthyroid) 
Diffuse     hyperplastic 
   Physiological 
   Pubertal 
   Pregnancy 
Multi Nodular Goitre 
 
Toxic 
Diffuse – Grave’s 
Multinodular 
Toxic Adenoma 
 
Neoplastic 
Benign 
Malignant 
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Inflammatory: 
 
Autoimmune -  Chronic Lymphocytic thyroiditis  
         Hashimoto’s thyroiditis 
Granulomatous - De Quervain’s thyroiditis 
Fibrosing  - Riedel’s thyroiditis 
Infective  - Acute (Bacterial, Viral, Subacute) 
      Chronic (TB, Syphilitic) 
Others  - Amyloid. 
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CLASSIFICATION OF HYPOTHYROIDISM 
 
 
Autoimmune thyroiditis (chronic lymphocytic) 
 
Non-goitrous - primary myxoedema 
Goitrous  - Hashimoto’s 
 
 
Iatrogenic 
 
After thyroidectomy 
After radioiodine theraphy 
Drug induced (anti-thyroid, PAS & Iodides in excess) 
 
Dyshormogenesis 
Goitrogens 
Secondary to pituitary or hypothalamic disease 
Thyroid agenesis 
Endemic Cretinism 
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CLASSIFICATION OF THYROID NEOPLASMS: 
 
Benign 
 
Follicular Adenoma 
 
Malignant 
 
Primary 
Follicular epithelium 
Differentiated  –  Follicular  
        Papillary 
Undifferentiated  –  Anaplastic 
Para follicular cells 
Medullary 
Lymphoid cells 
Lymphoma 
Secondary 
   Metastatic 
   Local infiltration 
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TNM STAGING OF THYROID CANCER. 
 
Tumour 
 
Tx - Primary can not be assessed 
To - No evidence of primary 
T1 - Limited to thyroid, < 1cm 
T2 - Limited to thyroid , >1cm but <4cm 
T3 - Limited to thyroid >4 cm 
T4 - Extending beyond capsule, any size 
 
Nodes 
 
Nx - Cannot be assessed 
No - No regional node metastasis 
N1 - regional node metastasis 
 
Metastasis 
 
Mx - Cannot be assessed 
Mo - No metastasis 
M1 - metastasis present 
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BREAST 
 
BENIGN BREAST DISORDERS CLASSIFICATION  
 
ANDI 
 
Cyclical nodularity and mastalgia 
Cysts 
Fibroadenoma 
 
Duct ectasia/periductal mastitis 
 
 
Pregnancy related 
 
 
Galactocele 
Puerperal abscess 
 
Congenital disorders 
 
Inverted nipple 
Supernumerary breasts/nipples 
Non-breast disorders 
Tietze’s disease 
35 
Sebaceous cysts and other skin conditions 
Risk of future Invasive breast carcinoma  
No increase 
  Adenosis 
  Apocrine metaplasia 
 Cysts, small or large 
 Mild hyperplasia (>2 but <5 cells deep) 
 Duct ectasia 
 Fibroadenoma 
 Fibrosis 
 Mastitis, inflammatory 
 Periductal mastitis 
 Squamous metaplasia 
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Slightly increased (RR 1.5-2) 
 Moderate or florid hyperplasia, Solid or papillary 
 Duct papilloma with fibrovascular core 
 Sclerosing adenosis, well-developed 
Moderately increased (RR 4-5) 
 Atypical hyperplasia, ductal or lobular 
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Foote & Stewart classification for invasive breast cancer: 
 
I. Paget’s disease of the nipple 
 
II. Invasive Ductal Carcinoma 
A. Adenocarcinoma with productive fibrosis (80%) 
B. Medullary carcinoma 
C. Mucinous (colloid) carcinoma 
D. Papillary carcinoma 
E. Tubular carcinoma 
 
 
 
 
III. Invasive lobular carcinoma 
 
IV. Rare cancer –  Adenoid cystic 
     Squamous cell 
Apocrine 
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TNM STAGING OF CARCINOMA BREAST 
 
 
Tumour 
 
Tx - Cannot be assessed 
To - No evidence of primary 
TIS - Insitu cancer 
T1 - Tumour < 2cm 
T2 - Tumour 2-5 cm 
T3 - Tumour > 5cm 
T4 - Any size invading skin or chest wall 
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Node 
 
Nx - cannot be assessed  
No - No regional node metastasis 
N1 - mobile Axillary nodes 
N2 - Fixed axillary nodes 
N3 - Ipsilateral Supraclavicular nodes 
 
Metastasis  
 
 
Mx - cannot be assessed 
Mo - No distant metastasis 
M1 - Distant metastasis 
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SOFT TISSUE SARCOMA 
 
 
Predisposing factors for sarcomas 
 Genetic predisposition 
  Neurofibromatosis 
  Li-Fraumeni syndrome 
  Retinoblastoma 
  Gardner’s Syndrome 
Radiation Exposure 
  Ortho and mega Voltage Therapeutic radiation 
Lymphedema 
  Post Surgical 
  Post Irradiation 
  Parasitic infection (Filariasis) 
 
 
 
41 
Trauma 
 Post parturition 
 Extremity 
Chemical 
 2.3,7,8 – Tetrachlorodibenzodioxin (TCDD) 
 Polyvinyl Chloride 
 Hemochromatosis 
 Arsenic 
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AJCC staging 
 
     Primary tumour (T) 
 
T1 - tumour ≤ 5 cm 
T1a - Superficial 
T1b -Deep 
 
T2 - Tumour > 5cm 
T2a- Superficial 
T2b- Deep 
 
 
Regional Lymph nodes (N) 
 
      N0 - No regional nodal metastasis 
      N1- Regional nodal metastasis 
 
Distant Metastasis 
 
     M0- No Distant metastasis 
     M1- Distant  Metastasis 
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Histological grade (G) 
 
    G1 - Well differentiated 
    G2 - Moderately Differentiated 
    G3 - Pooly Differentiated 
    G4 - Undifferentiated 
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Classification Of Cervical Lymphadenopathy 
 
Inflammatory   - Reactive hyperplasia 
 
Infective : 
 
Viral  - IM, HIV 
Bacterial - Streptococcus, Staphylococcus 
- Actinomycosis 
- TB 
- Brucellosis 
Protozoan - Toxoplasmosis 
 
Neoplastic 
 
Malignant : Primary – Lymphoma 
     Secondary – SCC 
     Known  Primary 
     Occult Primary 
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OBSERVATION AND RESULTS: 
 
This study was conducted in 200 patients who presented to 
TMCH with various types of swellings.  Out of these 200 patients, 
males were 40  and Females were 160.  As there were more number of 
breast and thyroid swellings in this study, Females out number the 
males. 
 
The overall accuracy of FNAC in diagnosis of common surgical 
conditions from this study was 80%. There were 40 negative FNACs out 
of theses 200 cases.  
 
Commonest causes for the breast lumps, presented here were, 
Fibroadenoma in case of benign swellings and Infiltrating ductal 
carcinoma among malignant varieties.  Sensitivity of FNAC for 
fibroadenoma was 94.4% whereas for IDC it was about 94.5%.   
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The sensitivity for fibroadenosis was 33.3% and for phylloides 
tumour was 66.6%. 
 
Among the thyroid tumours, the sensitivity for papillary thyroid 
carcinoma came to 80%, but for benign swellings like Nodular goiter 
and Adenoma was 76% &  71% respectively. 
 
FNAC sensitivity of TB adenitis, Lymphoma and metastatic node 
was 62.5%, 90.9% & 100% respectively.  Also reactive nodes were also 
diagnosed with 100% sensitivity. 
 
Parotid tumours, both benign and malignant, were shown to have 
FNAC sensitivity of 100%. 
 
Mesenchymal neoplasms were diagnosed with 80% sensitivity.   
Whereas the lipomas were correctly found out in 100% of patients. 
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False positivity rate in papillary thyroid carcinoma was 28.5% 
which is higher than the observation of other studies.  In case of Fibro 
adenoma, it was about 21.7%, whereas no case was reported falsely 
among Infiltrating ductal carcinoma patients. 
 
One case reported as lymphcyst thyroid turned out to be papillary 
carcinoma on Histopathological report. 
 
One MNG case was reported as Follicular neoplasm in FNAC. 
 
 Three patients who were reported as nodular goiter in FNAC, 
found to be having Thyroiditis (Autoimmune) from the Histopathology 
reports. 
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1.Breast 
 
Age (Years) 
 Diseases  
 FA Phylloides IDC 
10-20 22 - - 
21-30 10 1 4 
31-40 7 2 13 
41-50 - 1 9 
>50 - - 9 
 
2.Thyroid. 
 
Age 
(Years) 
 Diseases  
 Adenoma MNG PTC 
10-20    
21-30 2 10 2 
31-40  10 3 
41-50 2 5  
>50 2 1 1 
49 
3.Lymphnode 
 
Age 
(Years) 
Diseases 
 TB Lymphoma Metastasis
<10 1 - - 
11-20 2 3 - 
21-30 3 2 - 
31-40 - 2 1 
41-50 - 2 1 
>50 - 4 2 
 
4.Parotid 
 
Age 
(Years) 
Diseases 
 Pleomorphic 
Adenoma 
Carcinoma 
10-20  1 
21-30 2 2 
31-40  2 
41-50 1  
>50 2 2 
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DISCUSSION 
 
The literature sensitivity in the diagnosis of carcinoma breast was 
90-95%.  In our study it was 94.5% and almost matches the literature 
sensitivity. The commonest benign swelling of the breast, fibroadenoma, 
is also diagnosed with sensitivity of 94.4% 
 
Ashcroft & Von Henle achieved a diagnosis of Thyroid neoplasm 
in accuracy of over 90%.  Papillary thyroid carcinoma had accuracy of 
80% in this study. 
 
The sensitivity for lymphoma, Tuberculosis & metastasis node 
were 90.0%, 62.5% & 100% respectively from this study.   This almost 
approaches the recommended values from other studies of 84-98% for 
lymphoma and 90-96% for metastasis.  The study conducted at PGI, 
Chandigarh showed sensitivity for lymphoma, TB & Metastasis as 
64.7%, 60.4% and 71.5% respectively. 
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Karolinska produced accuracy of more than 90% in neoplasm’s of 
salivary glands.  In 1994 reviews, they produced sensitivity of 81-100% 
and accuracy of typing in 61-80%.  Our study results  were 100% 
sensitive to both benign and malignant neoplasms. 
 
The reported sensitivity of 100% for lipoma, 80% for 
mesenchymal malignancy in this study little bit contrasts the literature 
results of 85% for benign & 89% for malignant soft tissue tumours. 
 
The less sensitivity of FNA to the diagnosis of Fibrodenosis is 
due to variable responsiveness of breast tissue portions to hormonal 
stimuli and cytology taken from unrepresentative fibrous portions. 
 
The false positivity in case of papillary carcinoma & Follicular 
neoplasm in MNG may be due to papillary & Follicular pattern 
observed from the follicle lining epithelium, while they are in a  
 
52 
transforming sate of non-toxic to toxic.  This can be minimized by 
careful study of cytological features. 
 
Lymphomas would not be typed from the FNAC, even though it 
is reported as lymphoproliferative disorder.  So it would be better to go 
for excision biopsy if Lymphoma is suspected. 
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CONCLUSION 
 
1.     FNAC is highly sensitive in diagnosing malignancies of breast,  
    Thyroid and parotid. 
2. Lymphomas can be found out by FNAC but typing of 
lymphoma needs Excision biopsy. 
3. Benign swelling of breast (Fibrodenoma), parotid 
(Pleomorphic Adenoma), Soft tissue (Lipoma) can be 
diagnosed with high accuracy by FNAC. 
4. FNAC is useful in conjunction with clinical radiological 
findings to provide best possible initial assessment. 
5. The diagnostic accuracy not only depends on 
representativeness of the aspirate but also on the quality of 
cytological preparation. 
6. Repeat FNB samplings over a period of time reduces the false 
negative rates. 
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Sl. 
No. 
Name Age/ 
Sex 
IP No. Unit FNAC 
1. Latha 18/F 870487 S5 Fibroadenoma Fibroad
2. Thaiyalnayaki 50/F 871189 S4 Infiltrating Intra Ductal Ca Infiltrati
3. Meena  16/F 871182 S4 Fibroadenoma FA 
4. Janakiammal 60/F 869974  PTC PTC 
5. Tamil Selvi 37/F 871410 S3 Nodular goiter MNG 
6. Mukayee 51/F 869803 S3 IDC Infiltrati
7. Gomathy 30/F 14242  Nodular goiter Hashim
8. Jeyamary 47/F 871440 S3 IIDC IIDCa 
9. Vellaiyammal 39/F 872641 S4 Nodular goiter MNG 
10. Banumathy 35/F 76857 S4 Fibrocytic mastopathy Suppera
11. Renganayaki 60/F 872624 S4 Adenomatous goiter Adenom
microfo
12. Shanthimalar 20/F 873077 S6 FA FA 
13. Mahalakshmi 22/F 873195 S4 Nodule of Nodular Goitre MNG 
14. Sivanandham  43/M 873205 S4 Folicular Neoplasm MNG 
15. Latha 25/F 874166 S5 FA FA 
16. Vairaselvi 27/F 873831 S5 Nodule of Nodular goiter Nodule 
17. Viji 30/F 874504 S1 Fibroadenosis Sclerosi
18. Malarvizhi 35/F 873884 S5 Cystic degeneration in 
nodular goiter 
MNG 
19. Kuppammal 45/F 875476 S4 Ductal ca IIDC-N
20. Indira 36/F 874218 S2 Colloid goiter Simple c
21. Janaki 40/F 875245 S3 PCT PCT 
22. Manimegalai 38/F 813940 S3 Nodular goiter MNG 
23. Mary narchonai 30/F 875412 S1 FA Bn Phyl
24. Vijayalakshmi 21/F 875992 S2 FA FA 
25. Anuradha 18/F 876301 S1 FA Juvenile
26. Viji 30/F 876235 S1 Fibroadenosis IIDCA
27. Sivabagyam 24/F 876319 S4 FA Fibrocy
28. Susheela 39/F 876606 S3 Colloid nodule  MNG 
29. Thiruvarul Selvi 30/F 876748 S1 FA FA 
30. Ramamirtham 21/F 876761 S5 FA Fibroad
PTC – Papillary Thyroid Carcinoma ;  MNG – Multi Nodular Goiter;  FA – Fibroadenoma ; IDC-NOS -  Intra Du
otherwise specified ;  IIDC – Infiltrating Intraductual Carcinoma. 
31. Sarasu 29/F 876304 S4 Nodular goiter MNG 
32. Sathiba Begam 37/F 876969 S3 FA Fibrocy
33. Vijayalakshmi 55/F 131006 RT Ductal Ca IIDC 
34. Kawsalya 31/F 876318 S4 Nodular goiter MNG 
35. Chidambaram 53/M 876461 S5 Nodular goiter Hashim
36. Lakshmi 30/F 877875 S3 FA Fibrocy
37. Viji 30/F 876235 S1 ADH DCIS m
38. Pakiri 70/M 877562 S4 IDC IDC-NO
39. Parimala 19/F 878660 S2 FA FA 
40. Karthikeyini 47/F 876821 S5 Nodule of Nodular goiter MNG 
41. Mariammal 35/F 876973 S3 PTC PTC 
42. Anjammal 40/F 876945 S6 IDC IDC 
43. Vasantha 40/F 877750 S2 FA FA 
44. Amsavalli 30/F 876972 S3 
 
PTC PTC 
45. Maheswari 27/F 878780 S6 FA Fibro ad
46. Gunadevi 18/F 879518 S5 FA Fibroad
47. Jeenath Beevi 24/F 879072 S2 Fibroadenosis Fibroad
48. Manjula 35/F 879869 S4 FA FA 
49. Kuppammal 40/F 879411 S4 IDC IDC 
50. Logambal 55/F 876928 S6 Nodular goiter MNG 
51. Dharmaraj 42/M 876949 S6 Nodular goiter MNG 
52. Krishnambal 65/F 879512 S5 FA/ADH Mucinou
53. Mary 33/F 880358 S2 FA FA 
54. Revathy 37/F 879857 S1 IDC IDC 
55. Fathima 47/F 878054 S1 Nodular goiter Autoimm
56. Vasantha 29/F 880664 S4 Adenomatous goiter MNG 
57. Papathy 45/F 880316 S5 IDC IDC 
58. Kumudha 20/F 880950 S6 FA FA 
59. Vedhavalli 35/F 880181 S4 Cystosarcoma  Phyllodes 
tumour 
Maligan
60. Kalaiselvi 35/F 880797 S5 IDC Medulla
61. Ambika 45/F 881578 S2 FA Benign 
62. Roja 48/F 881701 S3 IDC IDC-NO
63. Chitra 24/F 882627 S6 FA FA 
64. Reka 24/F 882628 S8 FA FA 
ADH – Atypical Ductal Hyperplasia 
65. Shanthi 40/F 881872 S1 FA FA 
66. Vembu 42/F 882483 S2 Colloid goiter Simple C
67. Shanthi 22/F 883815 S6 FA FA 
68. Samanasa Mary 30/F 883829 S3 Fibroadenosis FA 
69. Janaki 52/F 881496 S1 IDC IDS-NO
70. Malar 36/F 884371 S3 Phylloides tumour Invasive
71. Pattu 60/F 883160 S1 IDC IDC-NO
72. Jeyamani 40/F 884723 S6 IDC IDC 
73. Saranya 18/F 885955 S2 FA Fibroad
74. Amsavalli 35/F 886317 S1 FA FA 
75. Susheela 49/F 884150 S2 IDC IDC-NO
76. Yogabalmi 35/F 886635 S4 Nodular goiter Hashim
77. Ramya 13/F 887859 S2 FA FA 
78. Janina Parveen 14/F 888160 S3 FA FA 
79. Kavitha 25/F 887280 S5 Adenomatous goiter Adenom
80. Sudha 18/F 888683 S1 FA Fibroad
81. Santhya 17/F 888335 S5 FA FA 
82. Rosi 18/F 888683 S1 FA Fibroad
83. Sahaya Mary 43/F 889370 S2 PCT Nodule 
84. Senthamarai 60/F 888966 S3 IDC IDC-NO
85. Jasmine 19/F 889552 S1 FA FA 
86. Vasantha  40/F 888872 S2 IDC IDC-NO
87. Visalatchi 45/F 900346 S1 IDC IDC-NO
88. Krishnaveni 20/F 900821 S2 FA FA 
89. Selvi 24/F 900010 S2 IDC IDC-NO
90. Sellamari 23/F 901290 S1 Adenomatous goiter MNG 
91. Malarvizhi 18/F 889257 S6 FA FA 
92. Poongothai 24/F 888184 S4 Nodular Colloid goiter Adenom
93. Saranya 18/F 889518 S1 FA FA 
94. Vijaya 37/F 889060 S5 PTC PTC 
95. Sasikala 18/f 889945 S4 FA FA 
96. Vasavi 18/F 890074 S2 FA Fibrocy
97. Sowharnisha 38/F 889947 S4 Nodular goiter Nodule 
98. Anchammal 37/F 889960 S1 FA FA 
99. Vellaiyammal 37/F 888852 S2 IDC IDC-Hig
100. Jothi 38/F 889935 S3 IDC IDC 
101. Saritha 20/F 900116 S3 FA FA 
102. Jeganathan 65/M 866203 S5 Mesenchymal Neoplasm Malig. P
103. Bhuvaneswari 24/F 867002 PS Postauricular dermoid Lymph 
104. Kasinathan 60/M 870722 S4 Lymphoproliferative 
disorder 
HL 
105. Muthulakshmi 9/F 1009110  Reactive Aderitis Reactive
106. Ramayee 40/F 870556 S3 Basal Cell Adenoma Basal C
107. Kumari 58/F 75911 S6 Mesenchymal Neoplasm Malig M
108. Pattammal 70/F 870015 S5 Mucoepidermoid Ca High gra
109. Jeyamary 56/F 871224 S6 Reactive hyperplasia Reactive
110. Settu 40/M 871679 S5 Metastatic deposits Meta SC
111. Nallammal 35/F 872294 S5 Lipoma Both Axilla Lipoma
112. Vidivelli 45/F 873405 S5 Lipoma Both Axilla Lipoma
113. Rajangam 54/M 872901 MGE HCC Adenoc
114. Mani 47/M 874504 S6 Dermoid Cyst Calcifie
115. Kalaiselvi 26/F 872889 S1 Lipoma Lipoma
116. Bharathy 19/M 873221 S5 GCT-Seminoma Embryo
117. Mahalakshmi 25/F 873205 S3 Lymphoproliferative 
disorder 
HL 
118. Sivaraman 42/M 874356 S6 Pleomorphic Ademona Pleomor
119. Karuppaiyan 59/M 873803 S2 Lipoma (Shoulder) Lipoma
120. Marimuthu 70/M 875561 S3 Pleomorphic Adenoma Monom
clear cel
121. Shanmugapriya 25/F 875316 S2 Granulomatous Adenitis Tubercu
122. Logambal 70/F 876011 S5 Monomorphic Adenoma Pleomor
123. Anthoniammal 68/F 875880 S4 Lipoma (arm) Lipoma
124. Martin 39/M 876978 S3 Low grade MPNST Low gra
125. Jothi 48/F 876863 S2 Lipoma Lipoma
126. Malliga Begam 45/F 876967 S3 Reactive hyperplasia Reactive
127. Gnanasoundar 8/M 79313 S6 Granulomatous 
Lymphadenitis 
Caseatin
128. Bhuvaneswari 21/F 876064 S6 Pleomorphic Ademona Pleomor
129. Chaurichandran 15/M 877201 S1 HL HL-Lym
130. Arjunan 63/M 877321 S5 Metastatic deposits Metasta
131. Baby 18/F 877474 S6 Reactive hyperplasia Caseatin
132. Govindaraj 43/M 877847 S6 Seminoma Mixed-G
HL – Hodgkins Lymphoma;  MPNST – Malignant Peripheral Nerve She th Tumour 
& embry
Nerosis
133. Chandrasekaran 23/M 876790 S1 Pleomorphic Adenoma Low gra
134. Vadivel 60/M 878471 S4 Chronic sialadenitis Chronic
(Subman
135. Chidambaram 48/M 878482 S4 Schwanoma Schwan
136. Wahitha Begam 32/F 878224 S2 Pleomorphic Adenoma Low gra
137. Thangavel 60/M 878978 S4 High grade mucoepidermoid 
ca 
High gra
138. Suba 35/F 879801 S5 Reactive Adenitis TB Ade
139. Jeyakumari 33/F 879989  Chronic Granulomatous 
adenitis 
Tubercu
140. Parthiban 35/M 87693  Pleomorphic Adenoma Pleomor
141. Parvathy 30/F 880293 S5 Chronic granulomatous 
Adenitis 
Tubercu
142. Chellammal 40/F 880187 S4 Metastatic Adenocarcinoma 
(Cervical Node) 
Metasta
143. Ramkumari 62/F 880592 S1 Pleomorphic Adenoma Pleomor
144. Nirmala 30/F 883329 S2 Chronic Sialadenitis Chronic
145. Parventhan 4/M 12112  Infected Cyst (Neck) Bronchi
146. Sarojini 28/F 884329 S6 Myoepithelial rich pleomor 
phic 
adenoma/Myoepithelioma 
Acinic c
147. Revathy 20/F 884197 S5 Lymphoproliferative 
disorder 
HL 
148. Periasamy 29/F 884488 S1 Lymphoproliferative 
disorder 
HL 
149. Manikandan 15/M 885844 S1 Low Gr.mucoepidermoid ca Low gra
150. Raja 26/M 992780 S6 TB Adenitis TB Ade
151. Velmurugan 35/M 901280 S1 Low grade mucoepidermoid 
ca 
Low gra
152. Sundarambal 45/F 889266 S2 Lymphoproliferative 
disorder 
HL 
153. Selvakumar 18/M 889312 S4 Granulomatous Adenitis TB Ade
154. Vasuki 40/F 873025 S3 IDC IDC-NO
155. Rajalakshmi 35/F 889021 S5 Nodular goiter Nodule 
156. Vallinayagam 45/F 901103 S4 IDC IDC-NO
157. Hathija Begam 40/F 908987 S4 Fibrocystic disease IDC 
158. Ramakrishnan 18/M 881132 S1 Lymphoproliferative 
disorder 
HL- Lym
159. Vasantha 57/F 906285 S4 MFH Sarcoma
160. Rani 27/F 846662 S5 Nodular goiter MNG 
161. Baby 30/F 846677 S2 Nodule of Nodular goiter MNG  w
Hemarrh
162. Amirthavalli 34/F 846382 S3 Phylloides tumour Maligna
163. Vijayam 40.F 847488 S5 Nodule of Nodular goiter MNG w
164. Menaka 23/F 14752 S5 FA Tubular
165. Selvi 33/F 84844. S6 IDC IDC-NO
166. Ponni 33/F 848114 S3 IDC IDC-NO
167. Ayyasami 40/M 847950 M1 Pleomorphic population of 
lymphocytes & scattered 
epitheloid cells 
Caseatin
lympade
168. Suganthi 17/F 848658 S4 FA FA 
169. Kanimozhi 26/F 848672 S4 FA Fibroad
170. Muniyandi 58/M 848222 S4 Lymphoproliferative 
disorder 
NHL 
171. Planivel 56/M 848477 S3 HL HL-Lym
variant
172. Narayanasamy 55/M 848017 S2 Lipoma Neck Lipoma
173. Parvathy 27/F 848605 S5 PCT MNG 
174. Pappathy 45/F 848345 S5 Adenomatous goiter Adenom
175. Chellappa 40/F 848946 S6 Lipoma Lipoma
176. Kala 25/F 849508 S4 Nodule of Nodular goiter MNG 
177. Indirani 50/F 848724 S3 IDC IDC wit
178. Latha 19/F 851273 S4 FA Fibroad
179. Soundaraj 50/M 21345 S5 Lymphoproliferative 
Changes 
NHL 
180. Manjula 25/F 850909 S2 FA FA 
181. Ulaganathan 40/M 851031 S2 Lipoma- (cervical region) Lipoma
182. Sudha 18/F 850978 S6 FA FA 
183. Suseela 40/F 851392  Fibrocystic disease, Atypical FA 
Hyperplasia 
184. Venkatachalam 53/M 878772 S2 Reactive Adenitis HL-Lym
185. Selvi 24/F 852154 S4 Nodular goiter MNG 
186. Rajendran 40/M 849875 S5 Lymphcyst Thyroid PCT 
187. Anjalai 60/F 851375 S2 IDC IDC-NO
188. Amsadevi 35/F 851528 S3 IDC IDC-NO
189. Maruthayee 55/F 851420  Adenoma Thyroid Follicul
190. Nagammal 60/F 852172 S4 IDC IDC-NO
191. Kasiammal 55/F 851922 S3 IDC IDC-NO
192. Sakila Banu 16/F 855068 S6 FA FA 
193. Viji 17/F 855065 S6 FA FA 
194. Tamilselvi 30/F 853508 S6 IDC IDC 
195. Pappa 30/F 852878 SI Nodule of Nodular goiter Adenom
196. Rosali 50/F  852882 S1 Nodular goiter MNG 
197. Muthukrishnan 29/M 8553945 S6 PCT PCT 
198. Latha 24/F 855876 S3 FA FA 
199. Silambuselvi 30/F 855934  IDC IDC 
200. Sathiya 30/M  RT Pleomorphic MFH Pleomor
 
NHL – Non Hodgkins Lymphoma 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
